

Prof. Dr. Matthias Theobald

*04.09.1960

Director of the III. Medical Clinic and Polyclinic
 Deputy Head of the University Center for Tumor Diseases (UCT)
 Professor of Hematology and Oncology
 Working Group Leader

III. Medical Clinic and Polyclinic
 University Medical Center of the Johannes Gutenberg University Mainz
 D-55131 Mainz, Langenbeckstr. 1
 Tel: +49-6131-17 7281, Fax: +49-6131-17 471658

direktor-3med@unimedizin-mainz.de

<http://www.unimedizin-mainz.de/3-med/arbeitsgruppen/ag-echchannaouihauptrocktheobald/team.html>

**Academia & Career**

- 1981 - 1987 Studies of chemistry, human biology and medicine at the universities of Gießen, Marburg, Mainz and Ulm
- 1987 Medical examination and approbation
- 1989 Doctorate Dr. med. (*summa cum laude*), Faculty of Clinical Medicine, University of Ulm
- 1987 - 1992 Research Assistant, Department of Internal Medicine III, Medical University Clinic Ulm
- 1992 - 1995 Scholar and Research Associate, *Department of Immunology, The Scripps Research Institute, La Jolla, CA*
- 1995 - 1996 Research Assistant / Assistant Doctor, III. Med. Clinic and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz
- 1996 Specialist in internal medicine
- 1997 Reputation as *Associate Professor, Medical College of Wisconsin, Bone Marrow Transplant Program und Joint Appointment als Associate Member, Blood Research Institute, Milwaukee, WI*
- 1996 - 2006 Senior physician, III. Medical Clinic and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz
- 1998 Habilitation, *venia legendi*, Innere Medizin, Internal Medicine, Department of Medicine, Johannes Gutenberg University Mainz
- 2000 Specialisation in haematology and internal oncology
- 2003 - 2006 University professorship (C3), *José Carreras endowed professorship*, III Med Clinic and Polyclinic, Department of Medicine, Johannes Gutenberg University Mainz
- 2004 - 2006 *Medical Director*, III. Med. Klinik and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz
- 2006 - 2009 Reputation as *Professor of Hematology, Director des Department of Hematology and Van Creveld Clinic, University Medical Center Utrecht, The Netherlands sowie Joint Appointment, Department of Immunology*
- 2007 - 2009 *Paul Klein Visiting Professor, Immunology Cluster of Excellence (ICE)*, Johannes Gutenberg University Mainz
- since 2008 Executive Board Member of the Research Center for Immunotherapy (FZI)
- since 2009 University Professorship (W3) for hematology / oncology, director of the III. medical clinic and polyclinic, university medical center of the Johannes Gutenberg University Mainz

- 2010 - 2013 Member of the Executive Board of the Centre for Thrombosis and Hemostasis (CTH), University Medicine of the Johannes Gutenberg University Mainz
- 2010 - 2013 Speaker of the Clinical Research Unit KFO 183 "Optimized Allogeneic Lymphocyte Therapy" of the German Research Foundation (DFG), University Medicine of the Johannes Gutenberg University Mainz
- since 2011 Spokesman of the Executive Board of the University Center for Tumor Diseases (UCT) Mainz, University Medicine of the Johannes Gutenberg University Mainz
- since 2013 Representation of the German Society for Haematology and Oncology (DGHO) in the Commission for Clinical Studies in Oncology of the German Cancer Society (DKG)
- since 2013 Speaker of the Mainz office within the German Consortium for Translational Cancer Research (DKTK), Frankfurt/Mainz office

Reviewer

Ad hoc reviewer for about 20 international journals, about 40 national, European and international institutions of research and research promotion.

Publisher

- 2008 – 2013 *Associate Editor*, Haematologica / The Hematology Journal
- since 2011 *Editorial Board*, Annals of Hematology
- since 2012 *Associate Editor*, Oncology

Awards

- 1990 Prize of the Ulm University Society
- 1990 Ludolf Krehl Prize of the Southwest German Society for Internal Medicine
- 1992 Artur Pappenheim Prize for Hematology of the German Society for Hematology and Oncology (DGHO) (together with D. Bunjes)
- 1993 *The Erich and Gertrud Roggenbuck Foundation Award for Research in Bone Marrow Transplantation der European Group for Blood and Marrow Transplantation (EBMT)*
- 1997 Vincenz Czerny Award for Oncology of the German Society for Haematology and Oncology (DGHO)
- 2001 *International Award for Research in Leukaemia by the Lady Tata Memorial Trust* (together with C. Lotz)

Memberships

- German Society for Haematology and Oncology
- German Working Group for Bone Marrow and Blood Stem Cell Transplantation
- European Group for Blood and Marrow Transplantation
- European Haematology Association
- The American Society of Hematology

Selected Publications

Echchannaoui H, Petschenka J, Antunes Ferreira E, Hauptrock B, Lotz-Jenne C, Voss RH, **Theobald M**. A potent tumor-reactive p53-specific single-chain TCR without on- or off-target autoimmunity in vivo. *Molecular Therapy*. 2018;27(1):261-71.

Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, **Theobald M**, Matzdorff AC, Ganser A, Döhner H, Schlenk RF. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. *Haematologica*. 2016;101(7):839-45.

Knies D, Klobuch S, Xue SA, Birtel M, Echchannaoui H, Yildiz O, Omokoko T, Guillaume P8, Romero P, Stauss H, Sahin U, Herr W, **Theobald M**, Thomas S, Voss RH. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. *Oncotarget*. 2016;7(16):21199-221.

Distler E, Albrecht J, Brunk A, Khan S, Schnürer E, Frey M, Mottok A, Jordán-Garrote AL, Brede C, Beilhack A, Madas A, Tomsitz D, **Theobald M**, Herr W, Hartwig UF. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice. *Int J Cancer*. 2016;138(5):1256-68.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, **Theobald M**, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. *Lancet Haematol*. 2015;2(10):e427-36.

Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, **Theobald M**, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. *Br J Haematol*. 2015;168(6):824-34.

Sasca D, Hähnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, Bullinger L, Strand S, Strand D, **Theobald M**, Kindler T. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. *Blood*. 2014;124(1):121-33.

Hähnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L, **Theobald M**, Kindler T. Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. *Blood*. 2014;123(15):2355-66.

Thomas S, Klobuch S, Besold K, Plachter B, Dörrie J, Schaft N, **Theobald M**, Herr W. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy. *Eur J Immunol*. 2012;42(12):3442-53.

T. Pabst, E. Vellenga, W. van Putten, H. C. Schouten, C. Graux, M.-C. Vekemans, B. J. Biemond, P. Sonneveld, J. Passweg, L. F. Verdonck, M.-C. Legdeur, **M. Theobald**, E. Emanuel, M. Bargetzi, J. Maertens, G. J. Ossenkoppele, and B. Löwenberg: Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. *Blood* 2012, 119(23): 5367-5373.